Search
Revolution Medicines Inc
RVMDAdd to Watchlist
192.620USD
+10.540+5.79%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
37.95BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-26The current earnings forecast score of Revolution Medicines Inc is 8.73, ranking 67 out of 387 in the Biotechnology & Medical Research industry. The average price target is 76.50, with a high of 99.00 and a low of 70.00.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
188.000
Target Price
+3.25%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Revolution Medicines Inc
RVMD
22
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Revolution Medicines Inc's expected revenue for the next quarter?
Revolution Medicines Inc's expected revenue is 2.42M.
What is Revolution Medicines Inc's price target?
Analysts forecast that Revolution Medicines Inc's price target is USD 76.50, with the highest forecast at USD 99.00 and the lowest forecast at USD 70.00.
How have Revolution Medicines IncRVMD's recent earnings per share performed?
The market expectation was USD -2.29, while Revolution Medicines IncRVMD's earnings per share (EPS) for the previous quarter was USD -1.88. EPS for the next quarter is expected at USD -1.96.
What is the analyst rating for Revolution Medicines Inc?
Based on the ratings of Revolution Medicines Inc's stock from 22 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
